Subscribe to read this content

Subscribe now

Created by an expert team of ophthalmologists and video game specialists (Tilak Healthcare), OdySight is a mobile medical game, used for close monitoring of patients with maculopathies. Prescribed as a medical device, the application offers digitized visual tests directly adapted from those performed in the medical office, as well as a puzzle game, stimulating cognitive and visual abilities. The application contributes to a better follow-up of the patient between treatments, allowing among other things, an early detection of the evolution of the disease.

Subscribe to read this content

Subscribe now

Context and Need

Age-related macular degeneration (AMD) is a chronic, degenerative disease affecting the central area of the retina, resulting in a progressive loss of central vision.

Read more...

Facts and Figures

Key Dates
Financing Phases
Awards & Certifications

Read more...

Team and Inner Circle

Edouard Gasser

Pr José-Alain Sahel 

Scientific Publications 

Read more...

Digital Solution

Tilak Healthcare is positioning itself to bring the concept of "play" into the monitoring of people with chronic eye diseases, with a tool that will have established medical reliability, similar to that of tests performed in doctors' offices, and that will make it possible to monitor patients who need it most.  "You Play, We Care" represents their slogan and their mission as a company.

Read more...

Value Proposition

Early Customers
Advantages and Differenciators

Read more...

Business Development

In order to promote OdySight, Tilak Healthcare has signed an exclusive co-promotion partnership with Novartis France in 2019. Tilak Healthcare relies on hospital and medical representatives from Novartis France to inform physicians about this innovation and allow greater access to this solution.

Read more...

Use Case at a Glance

Dr Quaranta has started prescribing OdySight in February 2020 (5 months of use at the time of our interview). She found the idea interesting. In her consultations, she has always insisted on self-monitoring without being sure that patients were doing it properly. She attended demonstrations by Tilak at the beginning of the project, then attended meetings with Novartis who presented the project. Thanks to these demonstrations and the discovery of the product, the doctor was able to conclude to that the system seems very sensitive and very effective.

Read more...